1. Home
  2. RNA vs LBTYA Comparison

RNA vs LBTYA Comparison

Compare RNA & LBTYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNA
  • LBTYA
  • Stock Information
  • Founded
  • RNA 2012
  • LBTYA 2004
  • Country
  • RNA United States
  • LBTYA Bermuda
  • Employees
  • RNA N/A
  • LBTYA N/A
  • Industry
  • RNA Biotechnology: Pharmaceutical Preparations
  • LBTYA Cable & Other Pay Television Services
  • Sector
  • RNA Health Care
  • LBTYA Telecommunications
  • Exchange
  • RNA Nasdaq
  • LBTYA Nasdaq
  • Market Cap
  • RNA 3.6B
  • LBTYA 3.6B
  • IPO Year
  • RNA 2020
  • LBTYA N/A
  • Fundamental
  • Price
  • RNA $29.17
  • LBTYA $9.96
  • Analyst Decision
  • RNA Strong Buy
  • LBTYA Buy
  • Analyst Count
  • RNA 14
  • LBTYA 5
  • Target Price
  • RNA $68.00
  • LBTYA $15.92
  • AVG Volume (30 Days)
  • RNA 1.4M
  • LBTYA 1.8M
  • Earning Date
  • RNA 08-08-2025
  • LBTYA 08-01-2025
  • Dividend Yield
  • RNA N/A
  • LBTYA N/A
  • EPS Growth
  • RNA N/A
  • LBTYA N/A
  • EPS
  • RNA N/A
  • LBTYA N/A
  • Revenue
  • RNA $8,927,000.00
  • LBTYA $4,421,800,000.00
  • Revenue This Year
  • RNA N/A
  • LBTYA $8.29
  • Revenue Next Year
  • RNA $156.80
  • LBTYA $0.74
  • P/E Ratio
  • RNA N/A
  • LBTYA N/A
  • Revenue Growth
  • RNA N/A
  • LBTYA 32.44
  • 52 Week Low
  • RNA $21.51
  • LBTYA $9.03
  • 52 Week High
  • RNA $56.00
  • LBTYA $21.56
  • Technical
  • Relative Strength Index (RSI)
  • RNA 43.92
  • LBTYA 52.33
  • Support Level
  • RNA $27.71
  • LBTYA $9.73
  • Resistance Level
  • RNA $30.52
  • LBTYA $10.38
  • Average True Range (ATR)
  • RNA 1.34
  • LBTYA 0.24
  • MACD
  • RNA -0.20
  • LBTYA 0.03
  • Stochastic Oscillator
  • RNA 36.40
  • LBTYA 54.84

About RNA Avidity Biosciences Inc.

Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.

About LBTYA Liberty Global Ltd.

Liberty Global is a holding company with interests in several telecom companies in the UK, the Netherlands, Belgium, Switzerland, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies, and has pursued a strategy since 2016 to merge or partner with mobile-network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.

Share on Social Networks: